Last reviewed · How we verify
NCT03093675
Robotic Assisted Surgery for Treatment of Gynecological Diseases: Pilot Study
NA trial testing TELELAP ALF-X Robotic Surgical System in Adnexal Diseases in 150 participants. Completed in 9 December 2014.
9 December 2014
Quick facts
| Lead sponsor | SOFAR S.p.A. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 23 October 2013 |
| Primary completion | 9 December 2014 |
| Estimated completion | 9 December 2014 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- TELELAP ALF-X Robotic Surgical System
Conditions studied
- Adnexal Diseases — all drugs for Adnexal Diseases →
- Uterine Diseases — all drugs for Uterine Diseases →
Sponsor
SOFAR S.p.A.
Who can join
18 and older, female only, with Adnexal Diseases or Uterine Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-center clinical trial. One hundred and fifty patients affected by adnexal and uterine diseases will be recruited to undergo treatment with robotic assisted laparoscopic procedures using the innovative TELELAP ALF-X Endoscopic Robotic Surgical System with the primary objective of assessing the feasibility, efficacy and safety of this approach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03093675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adnexal Diseases
Currently open trials in the same condition.
- NCT05761275 — Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach · NA · recruiting
Other SOFAR S.p.A. trials
Trials by the same sponsor.
- NCT04873063 — Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versu · Phase 1 · completed
- NCT04202692 — Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients · NA · completed
- NCT03883074 — Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsopha · NA · completed
- NCT03449628 — L. Casei DG® in Patients With Irritable Bowel Syndrome. · NA · completed
- NCT03793556 — Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03093675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SOFAR S.p.A.
- Last refreshed: 28 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03093675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing